SCHEMBL3559828

SCHEMBL3559828

FC(F)(F)c1cc(-c2ccc(Cl)c(Cl)c2)nc(I)n1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.48
HSD17B10 Q99714 2/20 0.48
ALDH1A1 P00352 1/20 0.48
KIF20B Q96Q89 1/20 0.44
TTR P02766 1/20 0.41
KMO O15229 3/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
AHR P35869 1/20 0.39
TP53 P04637 1/20 0.39
MAPT P10636 1/20 0.39
ADORA2A P29274 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SDHB P21912 1/20 0.38
PTGS2 P35354 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3565531 0.87 KDM4E (0.44) KDM4EHSD17B10ALDH1A1RAB9ATP53
SCHEMBL3564044 0.84 KDM4E (0.67) KDM4EHSD17B10ALDH1A1RAB9ATP53
SCHEMBL3557053 0.84 KMO (0.53) KDM4EHSD17B10ALDH1A1KIF20BTTR
SCHEMBL3560482 0.79 KDM4E (0.49) KDM4EHSD17B10ALDH1A1RAB9ATP53
SCHEMBL4657944 0.78 KDM4E (0.40) KDM4EHSD17B10ALDH1A1KIF20BTTR
SCHEMBL3560101 0.78 KMO (0.57) KDM4EHSD17B10ALDH1A1KIF20BTTR
SCHEMBL3565008 0.77 KMO (0.54) TTRKMO
SCHEMBL3566230 0.76 S1PR1 (0.45) KDM4EHSD17B10ALDH1A1KIF20BKMO
SCHEMBL3559710 0.76 KDM4E (0.43) KDM4EHSD17B10ALDH1A1KIF20BTTR
SCHEMBL3565024 0.75 KDM4E (0.45) KDM4EHSD17B10ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2001849-B1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2014-11-26 EP disclosed
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 KDM4E 2568/4885HSD17B10 3931/4885ALDH1A1 1138/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 KDM4E 1276/4885HSD17B10 3932/4885ALDH1A1 3286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.